Tumor suppressor p53 deficiency increases tumor immunogenicity through promoting IL33-mediated anti-tumor immune responses
Recent studies have shown that p53 contributes to poor survival during immune checkpoint
blockade (ICB) therapy. Lung cancer patients with p53 mutations have significantly …
blockade (ICB) therapy. Lung cancer patients with p53 mutations have significantly …
[PDF][PDF] Tumor suppressor p53 deficiency increases tumor immunogenicity through promoting IL33-mediated anti-tumor immune responses
Y Li, DS Gao, L Yi, F Gao, R Sun, KK Lu, J Xu… - scholar.archive.org
Recent studies have shown that p53 contributes to poor survival during immune checkpoint
blockade (ICB) therapy. Lung cancer patients with p53 mutations have significantly …
blockade (ICB) therapy. Lung cancer patients with p53 mutations have significantly …
Tumor suppressor p53 deficiency increases tumor immunogenicity through promoting IL33-mediated anti-tumor immune responses
Y Li, DS Gao, L Yi, F Gao, R Sun, KK Lu, J Xu… - 2022 - europepmc.org
Recent studies have shown that p53 contributes to poor survival during immune checkpoint
blockade (ICB) therapy. Lung cancer patients with p53 mutations have significantly …
blockade (ICB) therapy. Lung cancer patients with p53 mutations have significantly …